1. Home
  2. BBY vs BIIB Comparison

BBY vs BIIB Comparison

Compare BBY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBY
  • BIIB
  • Stock Information
  • Founded
  • BBY 1966
  • BIIB 1978
  • Country
  • BBY United States
  • BIIB United States
  • Employees
  • BBY N/A
  • BIIB N/A
  • Industry
  • BBY Consumer Electronics/Video Chains
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBY Consumer Discretionary
  • BIIB Health Care
  • Exchange
  • BBY Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • BBY 15.6B
  • BIIB 18.7B
  • IPO Year
  • BBY N/A
  • BIIB 1991
  • Fundamental
  • Price
  • BBY $78.96
  • BIIB $154.38
  • Analyst Decision
  • BBY Buy
  • BIIB Buy
  • Analyst Count
  • BBY 19
  • BIIB 24
  • Target Price
  • BBY $82.18
  • BIIB $174.62
  • AVG Volume (30 Days)
  • BBY 3.4M
  • BIIB 1.6M
  • Earning Date
  • BBY 11-25-2025
  • BIIB 10-30-2025
  • Dividend Yield
  • BBY 4.83%
  • BIIB N/A
  • EPS Growth
  • BBY N/A
  • BIIB N/A
  • EPS
  • BBY 3.63
  • BIIB 10.97
  • Revenue
  • BBY $41,598,000,000.00
  • BIIB $10,065,900,000.00
  • Revenue This Year
  • BBY $1.64
  • BIIB $2.97
  • Revenue Next Year
  • BBY $1.33
  • BIIB N/A
  • P/E Ratio
  • BBY $21.71
  • BIIB $14.18
  • Revenue Growth
  • BBY N/A
  • BIIB 4.77
  • 52 Week Low
  • BBY $54.99
  • BIIB $110.04
  • 52 Week High
  • BBY $95.49
  • BIIB $176.95
  • Technical
  • Relative Strength Index (RSI)
  • BBY 47.53
  • BIIB 59.29
  • Support Level
  • BBY $81.60
  • BIIB $148.90
  • Resistance Level
  • BBY $82.60
  • BIIB $157.79
  • Average True Range (ATR)
  • BBY 2.12
  • BIIB 4.78
  • MACD
  • BBY -0.62
  • BIIB 0.43
  • Stochastic Oscillator
  • BBY 17.91
  • BIIB 82.77

About BBY Best Buy Co. Inc.

With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Share on Social Networks: